Daily Stock Setups

Hapoalim: Teva to make acquisition in H1 of 2010: Gilad Sarig: There is little chance that generic Copaxone will hit the market

Posted on: Tue, 27 Oct 2009 16:34:00 EDT

Symbols: TEVA

Are you looking to increase your ETF knowledge?

Oct 27, 2009 (Globes - McClatchy-Tribune Information Services via COMTEX) --
TEVA | Quote | Chart | News | PowerRating -- Bank Hapoalim analyst Gilad Sarig gives Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA | Quote | Chart | News | PowerRating) an "Outperform" recommendation with a target price of $57 per share. He predicts that Teva will report earnings per share of $0.89 on $3.68 billion revenue, but also predicts that the company will beat the analysts' consensus, as it is wont to do.

Teva is due to publish its financial report on November 3. The analysts' consensus is earnings per share of $0.88 on $3.63 billion revenue.

Sarig notes the rising threat against Teva's multiple sclerosis drug, Copaxone, as two competitors, including Mylan Inc. (NYSE: MYL), have already submitted to the US Food and Drug Administration (FDA) applications for generic versions of the drug. The first company to obtain marketing certification will get marketing exclusivity for the cheaper generic version. This will hurt Teva, as Copaxone accounts for about a third of its total revenue. Teva argues that its Copaxone patents are valid through 2014, and has already sued Mylan for patent infringement, which has blocked FDA approval for 30 months, or until a court decision, whichever comes sooner. Sarig says, "There is little chance that generic Copaxone will reach the market before 2012."

In response to rumors that Teva might acquire Protalix Biotherapeutics Inc. (AMEX:PLX), Sarig said that the combination of Teva's large cash reserves ($1.8 billion at the end of June) and the economic crisis, which is forcing some companies to sell assets, has created acquisition opportunities for Teva.

"We believe that Teva is constantly scanning the market in order to find the most suitable candidates for it," says Sarig, and cites Germany's RatioPharm GmbH as an example, because Teva needs to strengthen its presence in Germany. "2011 is shaping up to be a challenging year in terms of opportunities. We therefore believe that the company will make an acquisition in the first half of 2010 in order to support subsequent profit growth in the long term too."

To see more of the Globes or to subscribe to the newspaper, go to
http://www.globes-online.com. Copyright (c) 2009, Globes, Tel Aviv, Israel
Distributed by McClatchy-Tribune Information Services. For reprints, email
tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax
to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave.,
Suite 303, Glenview, IL 60025, USA.

For full details on Teva Pharm Ind (TEVA) TEVA. Teva Pharm Ind (TEVA) has Short Term PowerRatings at TradingMarkets. Details on Teva Pharm Ind (TEVA) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.